Clinical Trial Update: A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME) [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating secukinumab 300 mg in adults with moderate-to-severe plaque psoriasis; completed with posted results in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis
• Plaque-type Psoriasis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Plaque Type Psorisis | Phase 3 | Status: COMPLETED | Results posted: 2019-04-23